Looking at the filing, I need to extract the key financial and operational data from this 10-Q. The filing text provided is primarily the cover page and forward-looking statements section, with the financial data tables not fully included in the extract. I'll work with what's disclosed. Let me identify the ticker from the cover page: "ELUT" on "The Nasdaq Capital Market" - so NASDAQ:ELUT. The filing is a 10-Q for the quarterly period ended September 30, 2026, filed November 10, 2026. Shares outstanding as of November 6, 2026: 44,397,650 shares of Class A common stock, no shares of Class B common stock. Key disclosed facts include: the sale of SimpliDerm Business to Cellution Biologics (up to $3 million in contingent payments), sale of Orthobiologics Business to Berkeley Biologics LLC, development of NXT-41 and NXT-41x, compliance issues with Nasdaq minimum bid price, and loan agreement with Avenue Venture Opportunities Fund II, L.P. and Avenue Growth Lending Fund III, L.P.

Elutia Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 10, 2026, disclosing operational updates, divestitures, and product development activities.

Key Highlights

  • Shares outstanding: As of November 6, 2026, the company reported 44,397,650 shares of Class A common stock and no shares of Class B common stock outstanding.
  • SimpliDerm divestiture: The company disclosed the sale of its former SimpliDerm Business to Cellution Biologics, with potential contingent technology transfer, commercial milestone, and earn-out payments of up to $3 million, subject to satisfaction of certain milestones and metrics.
  • Orthobiologics divestiture: The company also disclosed the prior sale of its former Orthobiologics segment to Berkeley Biologics, LLC, with potential post-closing earnout payments remaining.
  • Product pipeline: The company referenced ongoing development of NXT-41 and NXT-41x, described as next-generation biologic scaffolds, with NXT-41x incorporating local antibiotic delivery.
  • Nasdaq compliance risk: The filing identified the company's ability to regain compliance with Nasdaq's minimum bid price requirement as a risk factor.
  • Loan agreement: The company disclosed a loan and security agreement with Avenue Venture Opportunities Fund II, L.P. and Avenue Growth Lending Fund III, L.P., including a second tranche term loan subject to covenant compliance.

Elutia's Q3 2026 Quarterly Disclosure: Divestitures, Pipeline, and Capital Structure

Elutia Inc. (NASDAQ:ELUT), headquartered at 20 Firstfield Road, Gaithersburg, MD 20878, filed its Form 10-Q for the quarterly period ended September 30, 2026. The company is classified as a non-accelerated filer and a smaller reporting company, and confirmed it is not a shell company and not an emerging growth company, according to the filing.

The filing disclosed that Elutia has completed the sale of two former business segments. The SimpliDerm Business, which involved commercializing, manufacturing, distributing, selling, and marketing human acellular dermis products for breast reconstruction under the SimpliDerm brand, was sold to Cellution Biologics. According to the filing, up to $3 million in contingent payments may become payable, conditioned upon the satisfaction of certain milestones and metrics. Separately, the company's former Orthobiologics segment was sold to Berkeley Biologics, LLC, with potential post-closing earnout payments also referenced in the filing.

The company's forward-looking disclosures, which the filing states are subject to known and unknown risks and uncertainties, addressed the development of NXT-41 and NXT-41x, described as next-generation biologic scaffolds, and anticipated future interactions with the U.S. Food and Drug Administration regarding those products. The filing also flagged risks related to maintaining compliance with Nasdaq Capital Market listing requirements, including the minimum bid price requirement, as well as risks associated with warrant dilution and the ability to draw a second tranche term loan under its loan agreement with Avenue Venture Opportunities Fund II, L.P. and Avenue Growth Lending Fund III, L.P. The filing additionally referenced pending lawsuits and claims related to a recall of a single lot of Fiber Viable Bone Matrix (FiberCel) and a separate single lot of viable bone matrix (VBM).

What Was Disclosed

Elutia Inc. submitted its Form 10-Q for the quarter ended September 30, 2026, reporting 44,397,650 Class A shares outstanding as of November 6, 2026, disclosing two completed segment divestitures, ongoing NXT-41 and NXT-41x development, and several identified risk factors including Nasdaq compliance and loan covenant obligations.